Risk Prediction Model for Acute Kidney Injury After the First Course of Cisplatin
Cisplatin-associated acute kidney injury (C-AKI) is common. A  predictive model for C-AKI after the first course of cisplatin was developed and validated. 

The score based model was created using the patient’s age, cisplatin dose, hypertension, and serum albumin is predictive of C-AKI.
Research authors: Shveta S. Motwani, Gearoid M. McMahon, Benjamin D. Humphreys, Ann H. Partridge, Sushrut S. Waikar, Gary C. Curhan
Details Formula Study characteristics Files & References
★★★★
Model author
Model ID
1109
Version
1.3
Revision date
2018-01-29
Specialty
MeSH terms
  • Cisplatin
  • Acute Kidney Injury
  • Model type
    Custom model (Calculation)
    Status
    public
    Rating
    Share
    Formula

    Additional information

    Results C-AKI occurred in 13.6% of 2,118 patients in the development cohort and in 11.6% of 2,363 patients in the validation cohort.

    Data shown regards the patients in the development cohort

    Study Population

    Total population size: 2128
    Males: {{ model.numberOfMales }}
    Females: {{ model.numberOfFemales }}

    Continuous characteristics

    Name Mean SD Unit
    Age 56.8 13.2 Years
    Baseline creatinine 0.9 0.2 mg/dL
    Baseline eGFR 87.3 19.4 mL/min/1.73m^2
    Albumin 4.0 0.5 g/dL
    Height 169.3 9.8 cm
    Weight 170.4 42.0 lbs
    BMI 26.6 5.7 kg/m^2
    Name LL Q1 Median Q3 UL Unit
    Cisplatin dose 77 118.4 151 mg

    Categorical characteristics

    Name Subset / Group Nr. of patients
    Ethnicity White 1801
    Other 327
    Diabetes No 1828
    Yes 300
    Hypertension No 1082
    Yes 1046
    Fractioned dosing No 1792
    Yes 336
    Risk Prediction Model for Acute Kidney Injury After the First Course of Cisplatin
    V-1.3-1109.18.01.29
    Refer to Intended Use for instructions before use
    Evidencio B.V., Irenesingel 19, 7481 GJ, Haaksbergen, the Netherlands

    Related files

    No related files available

    Supporting Publications

    The calculated risk score for Cisplatin-associated acute kidney injury contains:
    ...
    Points

    {{ resultSubheader }}

    {{ model.survival.PITTitle }}

    {{ model.survival.YNETitle }}

    Result
    Note
    Notes are only visible in the result download and will not be saved by Evidencio

    The calculated risk score for Cisplatin-associated acute kidney injury contains: Points

    {{ resultSubheader }}
    {{ chart.title }}

    Outcome stratification

    Result interval {{ additionalResult.min }} to {{ additionalResult.max }}

    Conditional information

    Result interpretation

    See the stratified outcome to compare the frequency of C-AKI with the development and the validation cohorts used in the paper. 

    {{ file.classification }}

    Calculations alone should never dictate patient care, and are no substitute for professional judgement. See our full disclaimer.

    Comments
    Rating
    Comment
    Please enter a comment of rating
    Comments are visible to anyone

    Model feedback

    No feedback yet 1 Comment {{ model.comments.length }} Comments
    Not rated | On {{ comment.created_at }} {{ comment.user.username }} a no longer registered author wrote:
    logo

    Please sign in to enable Evidencio print features

    In order to use the Evidencio print features, you need to be logged in.
    If you don't have an Evidencio Community Account you can create your free personal account at:

    https://www.evidencio.com/registration

    Printed results - Examples {{ new Date().toLocaleString() }}


    Evidencio Community Account Benefits


    With an Evidencio Community account you can:

    • Create and publish your own prediction models.
    • Share your prediction models with your colleagues, research group, organization or the world.
    • Review and provide feedback on models that have been shared with you.
    • Validate your models and validate models from other users.
    • Find models based on Title, Keyword, Author, Institute, or MeSH classification.
    • Use and save prediction models and their data.
    • Use patient specific protocols and guidelines based on sequential models and decision trees.
    • Stay up-to-date with new models in your field as they are published.
    • Create your own lists of favorite models and topics.
    A personal Evidencio account is free, with no strings attached! Join us and help create clarity, transparency, and efficiency in the creation, validation, and use of medical prediction models.

    Disclaimer: Calculations alone should never dictate patient care, and are no substitute for professional judgement.